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Abstract
Background: Phenylketonuria (PKU) is often considered as the classical example of a genetic disorder in which
severe symptoms can nowadays successfully be prevented by early diagnosis and treatment. In contrast, untreated
or late-treated PKU is known to result in severe intellectual disability, seizures, and behavioral disturbances. Rarely,
however, untreated or late-diagnosed PKU patients with high plasma phenylalanine concentrations have been reported
to escape from intellectual disability. The present study aimed to review published cases of such PKU patients.
Methods: To this purpose, we conducted a literature search in PubMed and EMBASE up to 8th of September
2017 to identify cases with 1) PKU diagnosis and start of treatment after 7 years of age; 2) untreated plasma
phenylalanine concentrations ≥1200 μmol/l; and 3) IQ ≥80. Literature search, checking reference lists, selection
of articles, and extraction of data were performed by two independent researchers.
Results: In total, we identified 59 published cases of patients with late-diagnosed PKU and unexpected favorable
outcome who met the inclusion criteria. Although all investigated patients had intellectual functioning within the
normal range, at least 19 showed other neurological, psychological, and/or behavioral symptoms.
Conclusions: Based on the present findings, the classical symptomatology of untreated or late-treated PKU may need
to be rewritten, not only in the sense that intellectual dysfunction is not obligatory, but also in the sense that intellectual
functioning does not (re)present the full picture of brain damage due to high plasma phenylalanine concentrations.
Further identification of such patients and additional analyses are necessary to better understand these differences
between PKU patients.
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Background
Phenylketonuria (PKU; OMIM 261600) is an inborn error
of metabolism, characterized by impaired activity of the
hepatic enzyme phenylalanine hydroxylase (PAH; EC
1.14.16.1) that normally converts phenylalanine (Phe)
to tyrosine. Since the discovery of increased plasma Phe
concentrations (hyperphenylalaninemia) as the underlying
cause of intellectual disability (ID), (often intractable)
seizures, and severe behavioral disturbances by Følling in
the 1930s [1], two developments have strongly influenced
the course of the disease. In the 1950s, it was first shown
by Bickel that early institution of a Phe-restricted diet
could prevent severe neurocognitive dysfunction [2]. In
the 1960s, a diagnostic test was developed by Guthrie that
enabled mass screening for hyperphenylalaninemia [3]. As
a consequence, PKU became a model for other inborn
errors of metabolism, as it was the first disorder in which
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severe neurocognitive dysfunction could be prevented by
early initiation of treatment, the first disorder in which a
‘simple’ diet rather than a drug was the intervention, and
the first disease ever for which early diagnosis was possible
due to population based neonatal screening [4].
Today, 100 years after the birth of Guthrie, most countries
in the developed world have adopted population-based neo-
natal screening for PKU [5], and each infant with confirmed
PKU is immediately put on a Phe-restricted diet to reduce
plasma Phe concentrations to levels within the target range.
This combination of early diagnosis and initiation of treat-
ment has resulted in normal IQ for most PKU patients [6].
To aim at optimal neurocognitive and psychosocial outcome
of PKU patients, the recommended upper target plasma
Phe levels in both the first European guidelines and USA
consensus statement are based on the assumption that the
correlation between plasma Phe concentrations and neuro-
cognitive/psychosocial outcome is the same for all PKU
patients, which may not be true. At least some patients still
show mild neurocognitive and psychosocial impairments,
even when plasma Phe concentrations are only mildly ele-
vated (600–1200 μmol/l) [7–9]. On the other hand, rarely,
untreated or late-diagnosed PKU patients with very high
plasma Phe concentrations (> 1200 μmol/l) have been re-
ported to escape from ID [10, 11].
To investigate what these patients can teach us about
the inter-individual differences in brain vulnerability to
high plasma Phe between PKU patients, this study aimed
to review published cases of late-diagnosed PKU patients
without ID despite high plasma Phe concentrations.
Methods
Search strategy
We initially conducted a literature search on PubMed
and EMBASE without date limits up to 10th of August,
2016. In both PubMed and Embase, a search including
the following keywords (Mesh) and free text terms in
titles and abstracts (tiab) was entered: (“Phenylketonur-
ias”[Mesh] OR phenylketonuria*[tiab] OR pku [tiab] OR
Oligophrenia Phenylpyruvica [tiab]) AND (atypical*[tiab]
OR late diagnos*[tiab] OR late treat*[tiab] OR late
detect*[tiab] OR adult-onset [tiab] OR untreat*[tiab] OR
normal intelligen*[tiab] OR above average intelligen*[tiab]
OR normal intellect*[tiab] OR normal IQ [tiab] OR bor-
derline intelligen*[tiab] OR undiagnos*[tiab] OR unrec-
ogni*[tiab] OR mild phenylketonuria [tiab] OR mild
pku [tiab] OR mild hyperphenylalaninemia [tiab]).
This search was updated on 3rd of February and 8th
of September 2017.
Study and case selection
First, titles and/or abstracts of all identified non-duplicate
references were screened to select eligible studies. Eligibility
criteria included: 1) PKU patients being late-diagnosed/
−treated, and 2) information on IQ and plasma Phe con-
centrations being available. Then, full-text articles of the
selected references were retrieved and read independently
by two authors (DvV, AMJvW) to assess whether the inclu-
sion criteria were met. Studies were included if they de-
scribed at least one case meeting the following criteria: 1)
PKU diagnosis and/or start of treatment after 7 years of age
(based on the definition of untreated PKU as referring to
patients who are untreated at age 7 years or older [12]); 2)
untreated plasma Phe concentrations ≥1200 μmol/l; and 3)
IQ ≥80 (based on most previously used IQ scoring systems
that defined a normal intelligence as an IQ ≥80). This com-
bination of inclusion criteria was aimed to identify those
PKU patients representing the one end of the phenotypic
spectrum with regard to neurocognitive outcome in re-
lation to plasma Phe levels in untreated PKU patients.
Studies not describing detailed information on an indi-
vidual PKU patient were excluded. The reference lists
of all full-read articles were reviewed to identify additional
eligible studies. Selection of eligible articles, selection of
articles to be included, and extraction of data from se-
lected articles was performed independently by DvV and
AMJvW. Any inconsistencies were solved by discussion
among DvV, AMJvW, and FJvS. Results of the reviewing
process are outlined in Fig. 1. Physicians/treating centers
were contacted for possible further information about pre-
viously described cases that were included in our study.
Fig. 1 Outline of the reviewing process of the systematic literature
search as performed by DvV and AMJvW
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Results
In total, we identified 59 reported cases of late-diagnosed
(>7y) PKU patients without ID (as defined by an IQ
≥80), despite untreated plasma Phe concentrations of
≥1200 μmol/l (Additional file 1). Of all 59 reported
cases (Table 1), most patients had been diagnosed because
of a sibling with PKU, or because they had given birth to
children with PKU or children suffering from the maternal
PKU syndrome. In addition, ten cases were identified by
screening programs at adulthood. Most of these screening
programs were performed in women before or during
pregnancy to identify those being at risk of bearing chil-
dren suffering from the maternal PKU syndrome. In eight
cases, the reason for diagnosis was different or not re-
ported (cases #32 and #44). Case #9 was diagnosed be-
cause of high neonatal plasma Phe concentrations in
her child without any underlying enzymatic defect in
the offspring, and case #18 was diagnosed by a survey per-
formed in the hospital [13]. Other cases were diagnosed
because of cerebral symptoms. Case #2 presented at child-
hood with hyperactivity [14, 15]. Cases #41 and #42 pre-
sented at adolescence with neurological symptoms
(tremor and amaurosis fugax) but intact intellectual func-
tioning [16], and case #52 presented only at the age of
57 years with progressive spastic paraparesis and dementia
for four years [17]. Remarkably, case #52 also had a
late-diagnosed PKU sibling, but had never been investi-
gated for PKU. Of the 11 reported patients diagnosed with
PKU between 1-7y, three (27%) were diagnosed following
the identification of PKU in a sibling or relative, two (cases
#62 and #65) because of a positive urine ferric chloride
test on routine examination [18, 19], case #60 because of
the smell of phenylacetic acid [20], and two patients be-
cause of developmental delay (case #63 and #66) [15, 21].
Regarding the neurological outcome, of all 59 cases,
no (0%) seizures were described, but 4/10 were reported
to have an abnormal EEG. In addition, 12 cases (20%)
showed other neurological symptoms, primarily includ-
ing abnormal reflexes, movement disorders, and motor
difficulties. While, according to the inclusion criteria,
intellectual outcome was within the normal range for all
patients, ten patients (17%) had one or more problems
in neuropsychological or social functioning.
For 6 cases, additional neuroimaging and/or biochemical
information was provided. Cases #43 and #44 were de-
scribed to show only mild cerebral MRI abnormalities and
brain Phe levels as determined by magnetic resonance
spectroscopy (MRS) < 0.02 mmol/l, despite plasma Phe
concentrations > 1200 μmol/l [22, 23]. Also, no cere-
bral MRI abnormalities were observed in case #52 who
presented in adulthood with progressive spastic para-
paresis, dementia for four years, and high plasma Phe
concentrations [17], while cases #41 and #42 showed
MRI involvement scores that were comparable with
other late-diagnosed PKU patients [16]. Case #2, diag-
nosed at 9 years of age because of hyperactivity and
poor motor performance but normal IQ, was the one
patient for whom CSF analyses were reported, showing an
elevated Phe concentration of 456 μmol/l (at plasma Phe
of 1140–1500 μmol/l) [14].
Besides outcomes with respect to the central nervous
system, for some included PKU patients, physical char-
acteristics have been reported as well (data not shown).
Many of these PKU patients showed the typical physical
characteristics of untreated PKU: fair skin, blond hair,
blue eyes, and sometimes also eczema.
Discussion
This study describes cases of PKU patients without ID
despite late diagnosis with high plasma Phe concentra-
tions, representing one of the old, but still unresolved,
Table 1 Characteristics of late-diagnosed (> 7 years) PKU
patients who have escaped from intellectual disability despite
high plasma Phe concentrations
Patient characteristics Frequency (percentage)
Gender:
-male 12 (20%)
-female 45 (76%)
-not reported 2 (3%)
Reason diagnosis:
-PKU sibling 19 (32%)
-PKU offspring 8 (16%)
-affected offspring 19 (32%)
-screening 10 (17%)
-PKU relative 1 (2%)
-other 6 (10%)
-not reported 2 (3%)
Genetic confirmation of PAH deficiency
-yes 14 (24%)
-not reported 45 (76%)
Intellectual Quotient (IQ):
80–90 17 (29%)
90–100 16 (27%)
100–120 12 (20%)
≥ 120 2 (3%)
“normal” 12 (20%)
Neurological outcome:
-abnormal 17 (68%)
-no abnormalities (reported) 8 (32%)
Psychological/psychiatric/social outcome:
-abnormal 10 (48%)
-no abnormalities (reported) 11 (52%)
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questions in PKU. Most notable is the fact that we
identified so many published cases with unexpected favor-
able outcome. The second important observation was
that, although these patients had intellectual functioning
within the normal range (IQ ≥80), many showed other
(mild) cerebral PKU symptoms. The third remarkable
finding was that, in some of the PKU patients, neuro-
logical symptoms only started at adult age, although
this can still also be due to another disease rather than
PKU.
Classical symptomatology of untreated or late-treated
classical PKU consists of severe to global developmental
delay, seizures, psychiatric disorders, and profound ID,
with IQ declining to 40 or lower at one year of age [24].
Early natural history and cohort studies, however, also
showed that this severe clinical picture does not apply to
all PKU patients, postulating that approximately 1–2%
of the total PKU population would somehow have es-
caped from ID [10, 25]. However, based on the number
of identified PKU patients born before the introduction
of neonatal screening with severe ID that seems to be far
less than would be expected from the current prevalence
of classical PKU patients found at neonatal screening [26],
the incidence of such “unusual” PKU may be higher
than previously thought and many “unusual” PKU pa-
tients seem to have remained unidentified. This is further
substantiated by the number of classical PKU females with
normal intelligence who have been identified only because
of their children showing the maternal PKU syndrome,
resulting in 45 females and only 12 males being included in
Table 1, suggesting that especially “unusual” male PKU pa-
tients have remained unidentified. More recent calculations
based on screening programs for hyperphenylalaninemia in
pregnant women estimate that the percentage of “unusual”
PKU patients may be closer to 10% [27].
Besides the question how many PKU patients should
be classified as “unusual” (and might currently be over-
treated), the mechanisms underlying the lack of ID with-
out early diagnosis and treatment remain unresolved. It
has been hypothesized that these patients may have some
protecting mechanism, located at the blood-brain barrier
or within the brain itself, that is involved in Phe transport
or metabolism, or in the cerebral responses to high brain
Phe concentrations [22, 23] (Fig. 2). At the level of the
blood-brain barrier, LAT1 is considered to be the predom-
inant transporter for Phe and other large neutral amino
acids, and as such has been hypothesized to play a role in
the inter-individual differences in brain vulnerability to
high plasma Phe concentrations between PKU patients
[28]. However, the transport of Phe and other large neu-
tral amino acids across membranes of different cell types
within the brain is less well understood. In support of a
possible protecting mechanism located either at the
blood-brain barrier or within the brain itself, many “un-
usual” patients in the current review, besides high plasma
Phe concentrations, showed the physical PKU characteris-
tics of fair skin, blond hair, and blue eyes. Interestingly,
however, many of the here presented cases with normal
intellectual functioning show some other cerebral (e.g.
neurological or neuropsychological) PKU symptoms. More-
over, in contrast to the hypothesis of a possible variation in
Phe transport from blood to brain in these patients, Phe
concentrations in CSF of case #2 were correspondingly
high with their plasma Phe concentrations [14].
Fig. 2 Schematic picture outlining the hypotheses regarding the possible mechanism (s) underlying the inter-individual differences in brain
vulnerability to high plasma Phe concentrations between PKU patients including: 1) a difference in the transport of Phe and other large neutral
amino acids across the blood-brain barrier, 2) a difference in the transport of Phe and other large neutral amino acids across membranes of
different cell types within the brain, and 3) a difference in the vulnerability of one or more of the intracerebral processes to high brain
Phe concentrations
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Conclusion
To conclude, the old “unusual” PKU cases as described
in the present review give us more than the simple infor-
mation that they indeed exist. These cases at least suggest
that, even when ID is not seen, other neuropsychiatric
symptoms may still exist, suggesting that the pathophysi-
ology of brain dysfunction in PKU might relate to more
than one mechanism. We, therefore, do not only need pre-
cise description of late-diagnosed PKU patients with unex-
pected favorable outcome despite high plasma Phe, but also
need to further investigate these cases by modern tech-
niques such as metabolomics and next generation sequen-
cing to define the exact underlying mechanisms of PKU
brain dysfunction. The fact that more and more PKU pa-
tients are now diagnosed and treated from birth further
necessitates that we really find these patients right now.
Additional file
Additional file 1: Table S1. Reported and previously unreported cases
of late-diagnosed (> 7 years) PKU patients who have escaped from intellectual
disability despite high plasma Phe concentrations. (DOCX 52 kb)
Abbreviations
BBB: Blood-brain barrier; ID: Intellectual disability; LNAA: Large neutral
amino acids; PAH: Phenylalanine hydroxylase; Phe: Phenylalanine;
PKU: Phenylketonuria
Availability of data and materials
All data generated or analysed during this study are included in this
published article.
Authors’ contributions
DvV, AMJvW, and FJvS were involved in the design of the systematic
literature search. DvV and AMJvW performed the literature search and study
selection, primarily supervised by FJvS. DvV, AMJvW, and FJvS wrote the
manuscript. All other authors assessed the selected literature and made
important contributions to the revision of the manuscript. All authors read
and approved the final manuscript.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1University of Groningen, University Medical Center Groningen, Beatrix
Children’s Hospital, 9700, RB, Groningen, The Netherlands. 2Department of
Gastroenterology, Radboud University Medical Center, Nijmegen, The
Netherlands. 3Department of PKU, Kennedy Center, Copenhagen University
Hospital, Glostrup, Denmark. 4University Children’s Hospital, Jagiellonian
University, Krakow, Poland. 5Dietmar-Hopp Metabolic Center, University
Children’s Hospital, Heidelberg, Germany. 6Department of Pediatrics,
Cukurova University Faculty of Medicine, Adana, Turkey. 7Medical Genetics,
Sanford Health, Fargo, ND, USA. 8Mother and Child Health Care Institute of
Serbia Dr Vukan Cupic, School of Medicine, University of Belgrade, Belgrade,
Serbia. 9Department of Medical, Surgical and Neurological Sciences, Medical
School, University of Siena, Policlinico Santa Maria Alle Scotte, Siena, Italy.
10Department of Pediatrics, Hôpital d’Enfants Brabois, CHU Nancy,
Vandoeuvre les Nancy, France. 11Department of Pediatrics, Endocrinology,
Diabetology, Metabolic Diseases and Cardiology of the Developmental Age,
Pomeranian Medical University, Szczecin, Poland. 12Department of General
Pediatrics, Division of Neuropediatrics and Metabolic Medicine, Center for
Pediatric and Adolescent Medicine, University Hospital Heidelberg,
Heidelberg, Germany. 13Department of Pediatrics, Tawam Hospital, Al-Ain,
United Arab Emirates. 14Department of Internal Medicine, Division of
Endocrinology and Metabolism, Academic Medical Center, Amsterdam,
Netherlands. 15Department of Pediatrics, Oslo University Hospital, Oslo,
Norway. 16Clinic for Pediatrics, Inherited Metabolic Disorders, Medical
University of Innsbruck, Innsbruck, Austria. 17Metabolic Disease Unit, Sheba
Medical Center, Edmond and Lily Safra Children’s Hospital, Tel Aviv, Israel.
18Department of Pediatrics, Child Neurology and Psychiatry, Sapienza
University of Rome, Rome, Italy. 19Department of Internal Medicine, Oslo
University Hospital, Oslo, Norway. 20Genetics Division, Department of
Pediatrics, Keck School of Medicine, University of Southern California,
California, Los Angeles, USA. 21Department of Clinical Genetics, United
Laboratories, Tartu University Hospital and Institute of Clinical Medicine,
University of Tartu, Tartu, Estonia. 22Department of Genetics and Metabolism,
Chapel Hill hospital, University of North Carolina, Chapel Hill, USA.
23Department of Chemical Pathology and Metabolic Medicine, Guys and St
Thomas’ Hospitals NHS foundation trust, London, UK. 24Department of
General Pediatrics, Muenster University Children’s Hospital, Muenster,
Germany. 25Department of Pediatrics, Tehran University of Medical Sciences,
Tehran, Iran. 26Institute of Molecular Genetics and Genetic Engineering,
University of Belgrade, Belgrade, Serbia. 27Institute of Mother and Child,
Centre of Reproductive Health and Medical Genetics, Chisinau, Moldova.
28Newborn Metabolic Screening Unit, LabPlus, Auckland City Hospital,
Auckland, New Zealand. 29Departments of Pediatrics and Clinical Genetics,
Academic Medical Centre, Emma Children’s Hospital, Amsterdam, The
Netherlands. 30Department of Pediatrics, Centre for Molecular Medicine and
Therapeutics, University of British Columbia, Vancouver, Canada. 31Clinical
and Biochemical Genetics, Department of Pediatrics, The Hospital for Sick
Children and the University of Toronto, Toronto, Canada.
Received: 4 May 2018 Accepted: 12 August 2018
References
1. Fölling A. Uber Ausscheidung von Phenylbrenztraubensaure in den Harn als
Stoff wechselanomalie in Verbindung mit Inbicillitat. Ztschr Physiol Chem.
1934;227:169.
2. BICKEL H, GERRARD J, HICKMANS EM. Influence of phenylalanine intake on
phenylketonuria. Lancet. 1953;265(6790):812–3.
3. GUTHRIE R, SUSI A. A simple phenylalanine method for detecting
phenylketonuria in large populations of newborn infants. Pediatrics.
1963;32:338–43.
4. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376(9750):
1417–27.
5. Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJ, Adams
J. Current status of newborn screening worldwide: 2015. Semin Perinatol.
2015;39(3):171–87.
6. Jahja R, Huijbregts SCJ, de Sonneville LMJ, van der Meere JJ, Legemaat AM,
Bosch AM, Hollak CEM, Rubio-Gozalbo ME, Brouwers MCGJ, Hofstede FC, de
Vries MC, Janssen MCH, van der Ploeg AT, Langendonk JG, van Spronsen FJ.
Cognitive profile and mental health in adult phenylketonuria: a PKU-
COBESO study. Neuropsychology. 2017;31(4):437–47.
7. Jahja R, Huijbregts SC, de Sonneville LM, van der Meere JJ, van Spronsen FJ.
Neurocognitive evidence for revision of treatment targets and guidelines
for phenylketonuria. J Pediatr. 2014;164(4):895–9. e2
8. Jahja R, van Spronsen FJ, de Sonneville LM, van der Meere JJ, Bosch AM,
Hollak CE, Rubio-Gozalbo ME, Brouwers MC, Hofstede FC, de Vries MC,
Janssen MC, van der Ploeg AT, Langendonk JG, Huijbregts SC. Social-
cognitive functioning and social skills in patients with early treated
phenylketonuria: a PKU-COBESO study. J Inherit Metab Dis. 2016;39(3):
355–62.
9. Smith I, Knowles J. Behaviour in early treated phenylketonuria: a systematic
review. Eur J Pediatr. 2000;159(Suppl 2):S89–93.
van Vliet et al. Orphanet Journal of Rare Diseases  (2018) 13:149 Page 5 of 6
10. Hsia DY, O'Flynn ME, Berman JL. Atypical phenylketonuria with borderline or
normal intelligence. Am J Dis Child. 1968;116(2):143–57.
11. Primrose DA. Phenylketonuria with normal intelligence. J Ment Defic Res.
1983;27(Pt 4):239–46.
12. van Spronsen FJ, van Wegberg AM, Ahring K, Belanger-Quintana A, Blau N,
Bosch AM, Burlina A, Campistol J, Feillet F, Gizewska M, Huijbregts SC, Kearney
S, Leuzzi V, Maillot F, Muntau AC, Trefz FK, van Rijn M, Walter JH, MacDonald A.
Key European guidelines for the diagnosis and management of patients with
phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743–56.
13. COFFELT RW. Unexpected finding from a Pku newborn screening program.
Pediatrics. 1964;34:889–90.
14. ALLEN RJ, GIBSON RM. Phenylketonuria with normal intelligence. Am J Dis
Child. 1961;102:115–22.
15. Thompson AJ, Smith I, Brenton D, Youl BD, Rylance G, Davidson DC, Kendall
B, Lees AJ. Neurological deterioration in young adults with phenylketonuria.
Lancet. 1990;336(8715):602–5.
16. Leuzzi V, Trasimeni G, Gualdi GF, Antonozzi I. Biochemical, clinical and
neuroradiological (MRI) correlations in late-detected PKU patients. J Inherit
Metab Dis. 1995;18(5):624–34.
17. Kasim S, Moo LR, Zschocke J, Jinnah HA. Phenylketonuria presenting in
adulthood as progressive spastic paraparesis with dementia. J Neurol
Neurosurg Psychiatry. 2001;71(6):795–7.
18. MABRY CC, PODOLL E. Above average intelligence in untreated
phenylketonuria. J Pediatr. 1963;63:1038–40.
19. Culley PD. Another population of phenylketonuria? Studies on atypical
phenylketonurics. Dev Med Child Neurol. 1969;11(6):718–29.
20. ARMSTRONG MD, CARLISLE JW, LOW NL. Phenylketonuria; two unusual
cases. Lancet. 1956;271(6949):917–8.
21. Gostomzyk JG, Dressler F. Phenylketonuria with normal IQ. Klin Wochenschr.
1967;45(15):793–4.
22. Weglage J, Moller HE, Wiedermann D, Cipcic-Schmidt S, Zschocke J, Ullrich
K. In vivo NMR spectroscopy in patients with phenylketonuria: clinical
significance of interindividual differences in brain phenylalanine
concentrations. J Inherit Metab Dis. 1998;21(1):81–2.
23. Moller HE, Weglage J, Wiedermann D, Ullrich K. Blood-brain barrier
phenylalanine transport and individual vulnerability in phenylketonuria.
J Cereb Blood Flow Metab. 1998;18(11):1184–91.
24. Jervis GA. The clinical picture. In: Lyman FL, editor. Phenylketonuria;
1963. p. 52–61.
25. KNOX WE. An evaluation of the treatment of phenylketonuria with diets low
in phenylalanine. Pediatrics. 1960;26:1–11.
26. Murphy GH, Johnson SM, Amos A, Weetch E, Hoskin R, Fitzgerald B, Lilburn
M, Robertson L, Lee P. Adults with untreated phenylketonuria: out of sight,
out of mind. Br J Psychiatry. 2008;193(6):501–2.
27. Hanley WB. Finding the fertile woman with phenylketonuria. Eur J Obstet
Gynecol Reprod Biol. 2008;137(2):131–5.
28. Moller LB, Paulsen M, Koch R, Moats R, Guldberg P, Guttler F. Inter-individual
variation in brain phenylalanine concentration in patients with PKU is not
caused by genetic variation in the 4F2hc/LAT1 complex. Mol Genet Metab.
2005;86(Suppl 1):S119–23.
van Vliet et al. Orphanet Journal of Rare Diseases  (2018) 13:149 Page 6 of 6
